

Cynata Announces Dr. Geoff Brooke as Chairman of Board of Directors

Melbourne, Australia; 18 August 2020: Cynata Therapeutics Limited (ASX: CYP), a leading clinical-stage biotechnology company, specialising in cell therapeutics, is pleased to announce that Dr. Geoff Brooke has been appointed Chairman of its Board of Directors, effective 18 August 2020. This appointment follows Cynata's recent announcement of a planned world first Phase 3 clinical trial for an iPSC-based cell therapy in osteoarthritis. Outgoing Chairman, Dr. Paul Wotton, will remain on the Board as a Non-Executive Director.

Dr. Brooke has 30 years' experience in the healthcare and venture capital industries and his substantial life sciences and financial expertise will continue to be invaluable to the Cynata Board. Dr Brooke is the founder and former Managing Director of two leading life sciences venture capital firms, GBS Ventures and Medvest Inc, and has been the lead investor of numerous healthcare companies. He earned his Bachelor of Medicine / Surgery from the University of Melbourne, Australia and a Masters of Business Administration from IMEDE (now IMD) in Lausanne, Switzerland. He is Chairman of Actinogen Medical Limited (ASX: ACW) and a non-executive director of Acrux Limited (ASX: ACR).

Dr. Geoff Brooke said, *"I am delighted to be appointed Chairman of Cynata. Since joining the Board as Non-Executive Director in 2019, I have seen the Company make major advances and it is now extremely well placed to continue to drive shareholder value both through the conduct of multiple Phase 2 and Phase 3 clinical trials and through its corporate partnering activities. Cynata's unique and commercially viable therapeutic mesenchymal stem cell (MSC) platform production technology, Cymerus™, sets the company apart from other stem cell approaches and shows very exciting clinical potential as a treatment for graft-versus-host disease (GvHD). I am confident that further breakthrough results will be seen from our upcoming clinical trials. I look forward to working with Ross Macdonald and the team, as we continue to execute against our strategic plan."*

Dr. Paul Wotton, who has been a Non-Executive Director of Cynata since June 2016 and Chairman since February 2017, will continue as a Non-Executive Director. The Company extends warm thanks and appreciation to Paul for his role as Chairman over the past three-and-a-half years.

Dr. Paul Wotton said, *"I am pleased to transition the Chair's role to Geoff particularly following the recent addition of Dr. Darryl Maher, formerly of CSL, to strengthen the Board. Both Geoff and Darryl have significant and relevant experience to guide the Company's growth. Cynata has a world leading platform to develop and produce potent and reproducible MSCs that can treat numerous possible indications, including osteoarthritis, respiratory distress in COVID-19 and graft-versus-host disease (GvHD) where advanced clinical trials are scheduled to commence shortly."*

As part of Dr Brooke's appointment as Chairman and subject to shareholder approval, he will be granted 2 million options exercisable at \$0.97 each and expiring five years from the date of grant. The options will vest in monthly tranches, subject to continuous service up to the applicable vesting date, as follows: (i) 55,555 for the first 35 months from grant date; and (ii) 55,575 on the 36th month from grant date. Each option will be exercisable for one fully paid ordinary share. Dr Brooke, in his role as Chairman, will receive the same annual fee that was paid to Dr Wotton, being \$110,000 inclusive of superannuation.



Following the completion of an independent review of long term incentive plans and remuneration of board members across the Australian listed biotechnology sector, the Board has resolved to grant options as set out below under the Company's employee share option scheme. The options exercise price is \$0.97 reflecting a 45% premium to the 5-day VWAP up to and including 17 August 2020. This grant encourages each of the participants to have a greater involvement in the achievement of Cynata's objectives and the option exercise price represents a substantial premium to the current share price. The options will be for a term of 5 years and vesting in monthly tranches over the first 3 years, subject to continuous service up to the applicable vesting date. Each grant is conditional on shareholder approval, which will be sought at the 2020 annual general meeting of the Company. A summary of the planned option grants is set out below:

- Ross Macdonald – 1,500,000 options
- Darryl Maher – 300,000 options
- Stewart Washer – 300,000 options
- Paul Wotton – 300,000 options
- Peter Webse – 100,000 options

-ENDS-

Authorised for release by Dr Ross Macdonald, Managing Director & CEO

CONTACTS: Dr Ross Macdonald, CEO, Cynata Therapeutics, +61 (0)412 119343, ross.macdonald@cynata.com
Claire LaCagnina, U.S. Media Contact, +1 315.765.1462, clacagnina@6degreespr.com

About Cynata Therapeutics (ASX: CYP)

Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata's lead product candidate CYP-001 met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD) in a Phase 1 trial. Cynata plans to advance its Cymerus™ MSCs into Phase 2 trials for severe complications arising from COVID-19, GvHD, critical limb ischemia and into a Phase 3 trial for osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ MSC technology in preclinical models of asthma, diabetic wounds, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics Limited
Level 3, 62 Lygon Street, Carlton, Victoria 3053, Australia
PO Box 7165, Hawthorn North, Victoria 3122
T: + 613 9824 5254 F: + 613 9822 7735 E: info@cynata.com
ABN - 98 104 037 372